Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2001
12/27/2001WO2001098487A1 Polynucleotides and polypeptides linked to blood pressure regulation and/or fatigue
12/27/2001WO2001098486A1 Mutation associated with epilepsy
12/27/2001WO2001098483A1 Gene encoding novel protocadherin-like protein
12/27/2001WO2001098482A2 Liver-specific gene expression cassettes, and methods of use
12/27/2001WO2001098481A2 Renal regulatory elements and methods of use thereof
12/27/2001WO2001098476A1 Polynucleotides encoding human serine proteases
12/27/2001WO2001098473A2 Method for isolating and purifying a protein and resulting protein
12/27/2001WO2001098471A2 Human phosphodiesterases
12/27/2001WO2001098468A2 Proteases
12/27/2001WO2001098467A2 Regulation of human prostasin-like serine protease
12/27/2001WO2001098466A2 Regulation of human prostasin-like serine protease
12/27/2001WO2001098461A1 Micro-organisms active in the digestive environment
12/27/2001WO2001098455A2 Method for preparing a physiologically active il-18 polypeptide
12/27/2001WO2001098453A2 Modified construct downstream of the initiation codon for recombinant protein overexpression
12/27/2001WO2001098367A2 Neuroactive peptides for treatment of hypoxia and related conditions
12/27/2001WO2001098365A2 Peptide and polypeptide inhibitors of complement c1s
12/27/2001WO2001098364A2 Peptides, compositions and methods for the treatment of burkholderia cepacia
12/27/2001WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/27/2001WO2001098360A2 Gp354 nucleic acids and polypeptides
12/27/2001WO2001098356A1 Low oxygen affinity mutant hemoglobins
12/27/2001WO2001098355A2 Cgi-69 compositions and methods of use
12/27/2001WO2001098354A2 Human receptors
12/27/2001WO2001098353A2 Secreted proteins
12/27/2001WO2001098352A2 Thrombomodulin analogs for pharmaceutical use
12/27/2001WO2001098351A2 G-protein coupled receptors
12/27/2001WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease
12/27/2001WO2001098348A2 Regulation of cellproliferation and differentiation using topically applied peptides
12/27/2001WO2001098347A1 Canine liver cell growth factor
12/27/2001WO2001098346A2 Methods and compositions for the treatment of peripheral artery disease
12/27/2001WO2001098345A1 Growth factors, nucleic acid encoding them and methods for identification
12/27/2001WO2001098344A2 Angiogenesis-modulating compositions and uses
12/27/2001WO2001098343A2 Conserved diaphanous-related formin autoregulatory domain (dad)
12/27/2001WO2001098341A1 Novel polypeptide and its dna
12/27/2001WO2001098340A2 Regulation of human mast cell protease 6-like enzyme
12/27/2001WO2001098337A1 A novel polypeptide, a human uteroglobin 9 and the polynucleotide encoding the polypeptide
12/27/2001WO2001098336A1 A novel polypeptide, a human s4 ribosomal protein 10 and the polynucleotide encoding the polypeptide
12/27/2001WO2001098333A2 Modification of hepatitis b core antigen
12/27/2001WO2001098332A2 Secreted redox proteins
12/27/2001WO2001098331A2 Glucagon-like peptide-1 analogs
12/27/2001WO2001098328A2 Glycopeptide phosphonate derivatives
12/27/2001WO2001098327A2 Glycopeptide carboxy-saccharide derivatives
12/27/2001WO2001098325A1 Methods for treating and preventing alopecia
12/27/2001WO2001098324A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
12/27/2001WO2001098323A2 G-protein coupled receptors
12/27/2001WO2001098321A1 Inhibition of human squamous cell carcinoma in vivo by egfr antisense rna
12/27/2001WO2001098294A2 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
12/27/2001WO2001097861A2 Vitronectin receptor antagonist pharmaceuticals
12/27/2001WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
12/27/2001WO2001097856A2 An orphan nuclear receptor
12/27/2001WO2001097851A2 Compositions and methods to improve the oral absorption of antimicrobial agents
12/27/2001WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001WO2001097848A2 Vitronectin receptor antagonist pharmaceuticals
12/27/2001WO2001097846A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/27/2001WO2001097841A2 Qs-21 and il-12 as an adjuvant combination
12/27/2001WO2001097835A1 Matrix protein compositions for inhibition of epithelial cell growth
12/27/2001WO2001097834A1 Matrix protein compositions for dentin regeneration
12/27/2001WO2001097833A1 Osteoclast secreted chemokine and uses thereof
12/27/2001WO2001097832A1 Pharmaceutical preparations containing cyclosporines and neutral oils
12/27/2001WO2001097831A1 Preventives or remedies for heart failure
12/27/2001WO2001097830A1 Modification of mdm2 activity
12/27/2001WO2001097829A2 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
12/27/2001WO2001097828A2 Rhob as a suppressor of cancer cell growth and cell transformation
12/27/2001WO2001097827A1 Mhc peptides over-expressed on prostate cancer cells and methods of use
12/27/2001WO2001097826A2 Hemostatic compositions, devices and methods
12/27/2001WO2001097817A1 Health promoting foods
12/27/2001WO2001097774A2 Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents
12/27/2001WO2001097771A2 Preparations that contain an extract of the plant pistia stratiotes
12/27/2001WO2001097770A1 Method for protecting human skin
12/27/2001WO2001097752A2 Compositions comprising urokinase for modulating muscle contractility and angiogenisis
12/27/2001WO2001097608A2 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods
12/27/2001WO2001097607A2 Transgenic animal model of neurodegenerative disorders
12/27/2001WO2001078894A9 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
12/27/2001WO2001070967A3 Regulation of human serotonin-like g protein-coupled receptor
12/27/2001WO2001070254A9 Use of human not1 and not1a orphan receptors
12/27/2001WO2001066116A8 Method for modulating tumor growth and metastasis of tumor cells
12/27/2001WO2001062086A8 Nutritional intervention composition for enhancing and extending satiety
12/27/2001WO2001059088A3 Vector
12/27/2001WO2001055310A3 Nucleic acids, proteins, and antibodies
12/27/2001WO2001053505A3 Herpes virus strains for gene therapy
12/27/2001WO2001051608A3 Hybrid cells obtainable from antigen presenting cells
12/27/2001WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity
12/27/2001WO2001046256A3 Vesicle trafficking proteins
12/27/2001WO2001045738A3 Use of heat shock proteins to enhance production of chemokines by a cell
12/27/2001WO2001045650A3 Cosmetic use of the residues from wine production
12/27/2001WO2001044278A3 Antigen preparations
12/27/2001WO2001043760A3 Use of ucp3 polynucleotides and polypeptides
12/27/2001WO2001039795A3 Attenuation of fibroblast proliferation
12/27/2001WO2001035975A3 Treatment of subnormal bone mineral density
12/27/2001WO2001032711A3 Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
12/27/2001WO2001029215A3 N-cam homolog and splice variants thereof
12/27/2001WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent
12/27/2001WO2001000803A3 Apolipoprotein a-iv-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
12/27/2001WO2001000799A8 Novel protein and dna thereof
12/27/2001WO2000064864A9 N-protected amines and their use as prodrugs
12/27/2001WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof
12/27/2001WO2000054785A9 Stabilized bicyclo[3.3.1]nonenes and methods of use
12/27/2001US20010056180 Enzyme inhibitor; for the prevention of enzyme induced tissue damage; for treatment of respiratory disorders
12/27/2001US20010056179 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
12/27/2001US20010056178 Inhibitors of protein synthesis, cell growth and tumorigenesis, and enhancers of apoptosis
12/27/2001US20010056125 Local anesthetic methods and kits
1 ... 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 ... 3163